Published in PLoS One on July 21, 2011
Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 2.39
The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One (2012) 2.05
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab (2013) 1.76
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest (2016) 1.36
Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS One (2013) 1.18
CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network. Neoplasia (2013) 1.11
Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid (2012) 1.08
Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab (2015) 0.98
Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. Oncogene (2015) 0.96
Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment. Front Endocrinol (Lausanne) (2013) 0.92
The expression of tumor-associated macrophages in papillary thyroid carcinoma. Endocrinol Metab (Seoul) (2013) 0.92
Immune response in thyroid cancer: widening the boundaries. Scientifica (Cairo) (2014) 0.84
Expression and function of connexin 43 in human gingival wound healing and fibroblasts. PLoS One (2015) 0.84
Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat Rev Clin Oncol (2016) 0.84
A mathematical model of the enhanced permeability and retention effect for liposome transport in solid tumors. PLoS One (2013) 0.84
Regulation of hemichannels and gap junction channels by cytokines in antigen-presenting cells. Mediators Inflamm (2014) 0.83
Tumor-Associated Mast Cells in Thyroid Cancer. Int J Endocrinol (2015) 0.83
miRNA expression in anaplastic thyroid carcinomas. PLoS One (2014) 0.83
The immune network in thyroid cancer. Oncoimmunology (2016) 0.80
New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer. BMC Genomics (2015) 0.80
Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. Br J Cancer (2014) 0.79
Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. J Clin Endocrinol Metab (2016) 0.78
Macrophages facilitate coal tar pitch extract-induced tumorigenic transformation of human bronchial epithelial cells mediated by NF-κB. PLoS One (2012) 0.78
Modulation of the tumor microenvironment for cancer treatment: a biomaterials approach. J Funct Biomater (2015) 0.78
The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. Oncotarget (2016) 0.78
Expression of decoy receptor 3 in diffuse sclerosing variant of papillary thyroid carcinoma: correlation with M2 macrophage differentiation and lymphatic invasion. Thyroid (2013) 0.76
Treatment of distant metastases from follicular cell-derived thyroid cancer. F1000Prime Rep (2015) 0.75
Transcriptional and metabolic reprogramming induce an inflammatory phenotype in non-medullary thyroid carcinoma-induced macrophages. Oncoimmunology (2016) 0.75
Cell Cycle M-phase Genes are Highly Upregulated in Anaplastic Thyroid Carcinoma. Thyroid (2016) 0.75
The expression of tumor-associated macrophages in papillary thyroid carcinoma. Endocrinol Metab (Seoul) (2013) 0.75
Thyroid Cancer Metabolism: A Review. J Thyroid Disord Ther (2016) 0.75
Macrophages form functional vascular mimicry channels in vivo. Sci Rep (2016) 0.75
Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E). Cancer Lett (2015) 0.75
TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells. Oncotarget (2016) 0.75
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol (2017) 0.75
Network biology: understanding the cell's functional organization. Nat Rev Genet (2004) 36.62
Error and attack tolerance of complex networks Nature (2000) 27.90
The large-scale organization of metabolic networks. Nature (2000) 27.57
Alternative activation of macrophages. Nat Rev Immunol (2003) 27.53
Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 26.08
Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol (2006) 21.58
The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev (2007) 21.13
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
The Ki-67 protein: from the known and the unknown. J Cell Physiol (2000) 16.48
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 13.79
Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 9.29
The many faces of macrophage activation. J Leukoc Biol (2003) 8.95
Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res (1991) 6.99
Formation and function of the myofibroblast during tissue repair. J Invest Dermatol (2007) 6.11
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res (1998) 5.86
The origin and function of tumor-associated macrophages. Immunol Today (1992) 5.12
Plasma membrane channels formed by connexins: their regulation and functions. Physiol Rev (2003) 4.87
Expression of the CD34 gene in vascular endothelial cells. Blood (1990) 4.41
Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev (2006) 4.02
Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst (2002) 3.77
Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med (1992) 3.31
Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol (2009) 3.23
Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res (2008) 2.96
Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res (2005) 2.83
The macrophage scavenger receptor CD163. Immunobiology (2005) 2.44
Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol (2006) 2.40
New approaches for imaging tumour responses to treatment. Nat Rev Cancer (2008) 2.38
The gap junction cellular internet: connexin hemichannels enter the signalling limelight. Biochem J (2006) 2.24
Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer (2008) 2.11
Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry. Ann Rheum Dis (2004) 2.09
Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc Res (2001) 2.05
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol (2007) 1.99
The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer (2010) 1.97
Selective permeability of gap junction channels. Biochim Biophys Acta (2004) 1.89
Invadopodia and podosomes in tumor invasion. Eur J Cell Biol (2005) 1.75
Hydrogen peroxide as a cell-survival signaling molecule. Antioxid Redox Signal (2009) 1.63
Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol (2009) 1.62
Tks5-dependent, nox-mediated generation of reactive oxygen species is necessary for invadopodia formation. Sci Signal (2009) 1.56
Facilitative glucose transporter gene expression in human lymphocytes, monocytes, and macrophages: a role for GLUT isoforms 1, 3, and 5 in the immune response and foam cell formation. Blood Cells Mol Dis (2004) 1.52
Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol (1996) 1.51
Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. J Leukoc Biol (2009) 1.51
Connexins: a myriad of functions extending beyond assembly of gap junction channels. Cell Commun Signal (2009) 1.49
CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol (2005) 1.34
Microglia proliferation is regulated by hydrogen peroxide from NADPH oxidase. J Immunol (2006) 1.33
Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene (2007) 1.18
Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res (2009) 1.17
Superoxide radical potentiates invasive capacity of rat ascites hepatoma cells in vitro. Cancer Lett (1986) 1.17
Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med (1996) 1.15
Induction of the CD163-dependent haemoglobin uptake by macrophages as a novel anti-inflammatory action of glucocorticoids. Br J Haematol (2002) 1.15
Intercapillary distance measurement as an indicator of hypoxia in carcinoma of the cervix uteri. Int J Radiat Oncol Biol Phys (1986) 1.12
Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep (2007) 1.12
Gap junctions and connexin-mediated communication in the immune system. Biochim Biophys Acta (2004) 1.12
Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid (1998) 1.11
Connexin 43 confers resistance to hydrogen peroxide-mediated apoptosis. Biochem Biophys Res Commun (2007) 1.05
A subpopulation of peritoneal macrophages form capillarylike lumens and branching patterns in vitro. J Cell Mol Med (2006) 0.98
Macrophage potentiation of invasive capacity of rat ascites hepatoma cells. Cancer Res (1987) 0.97
Anaplastic thyroid carcinoma. Immunocytochemical study of 32 cases. Am J Clin Pathol (1991) 0.95
Regulation of cancer invasion by reactive oxygen species and Tks family scaffold proteins. Sci Signal (2009) 0.94
The structure and signalling functions of the invariant T cell receptor components. Semin Immunol (1990) 0.93
Cx43 has distinct mobility within plasma-membrane domains, indicative of progressive formation of gap-junction plaques. J Cell Sci (2009) 0.92
18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging (2010) 0.91
Monocytes form a vascular barrier and participate in vessel repair after brain injury. Blood (2005) 0.91
Phenotypic overlap between monocytes and vascular endothelial cells. Adv Exp Med Biol (2003) 0.90
In vitro transformation of monocytes and dendritic cells into endothelial like cells. Adv Exp Med Biol (2003) 0.90
CD68 is not a macrophage-specific antigen. Ann Rheum Dis (2005) 0.90
18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid (2008) 0.87
Migration of monocytes/macrophages in vitro and in vivo is accompanied by MMP12-dependent tunnel formation and by neovascularization. Cold Spring Harb Symp Quant Biol (2002) 0.83
Control of fructose 2,6-bisphosphate levels in rat macrophages by glucose and phorbol ester. FEBS Lett (1989) 0.80
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol (2006) 6.57
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol (2005) 3.20
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol (2010) 3.11
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
A novel host defense system of airways is defective in cystic fibrosis. Am J Respir Crit Care Med (2006) 2.61
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med (2014) 2.51
Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med (2008) 2.47
Progress in molecular-based management of differentiated thyroid cancer. Lancet (2013) 2.44
Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. Ann Surg (2012) 2.35
Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab (2008) 2.30
Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol (2008) 2.23
Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol (2008) 2.23
Assessment of the cost of fine-needle aspiration cytology as a diagnostic tool in patients with thyroid nodules. Am J Clin Pathol (2008) 2.18
Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood (2008) 2.12
Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab (2007) 2.06
Management of retropharyngeal node metastases from thyroid carcinoma. World J Surg (2015) 1.98
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86
Dual oxidase2 is expressed all along the digestive tract. Am J Physiol Gastrointest Liver Physiol (2004) 1.84
Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol (2002) 1.81
New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab (2008) 1.76
New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol (2007) 1.74
Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab (2007) 1.72
Dual oxidase-2 has an intrinsic Ca2+-dependent H2O2-generating activity. J Biol Chem (2005) 1.67
Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab (2005) 1.64
Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a french area with very high whole-cell vaccine coverage. J Infect Dis (2002) 1.57
Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol (2002) 1.51
Expanding indications for recombinant human TSH in thyroid cancer. Thyroid (2008) 1.49
Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol (2005) 1.46
A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab (2006) 1.45
Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood (2011) 1.43
Medullary thyroid carcinoma. Clin Endocrinol (Oxf) (2004) 1.42
Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med (2007) 1.42
Radiation dose to the pancreas and risk of diabetes mellitus in childhood cancer survivors: a retrospective cohort study. Lancet Oncol (2012) 1.41
Ernest L. Mazzaferri, MD, MACP (1936-2013). Thyroid (2013) 1.39
Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res (2013) 1.36
The Pseudomonas toxin pyocyanin inhibits the dual oxidase-based antimicrobial system as it imposes oxidative stress on airway epithelial cells. J Immunol (2008) 1.35
The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol (2009) 1.32
Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer (2013) 1.31
Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol (2013) 1.31
Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab (2006) 1.30
Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res (2012) 1.30
Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol (2005) 1.30
Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab (2005) 1.30
Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer (2002) 1.28
Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer (2006) 1.26
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest (2004) 1.26
Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res (2011) 1.25
Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. Blood (2005) 1.22
KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol (2005) 1.21
Intracellular expression of reactive oxygen species-generating NADPH oxidase NOX4 in normal and cancer thyroid tissues. Endocr Relat Cancer (2010) 1.20
Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol (2005) 1.18
131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med (2008) 1.17
Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab (2003) 1.17
Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol (2008) 1.17
Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab (2007) 1.16
ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res (2008) 1.15
Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.15
Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid (2002) 1.13
Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab (2012) 1.11
Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes. J Clin Endocrinol Metab (2002) 1.11
Cisplatin resistance associated with PARP hyperactivation. Cancer Res (2013) 1.11
Prion protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced cell death. Cancer Res (2004) 1.10
Germ-line DNA polymorphisms and susceptibility to differentiated thyroid cancer. Lancet Oncol (2009) 1.09
Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc Natl Acad Sci U S A (2002) 1.09
Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am J Pathol (2005) 1.09
Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer (2004) 1.09
High rate of multifocality and occult lymph node metastases in papillary thyroid carcinoma arising in thyroglossal duct cysts. Ann Surg Oncol (2009) 1.08
γ-H2AX and other histone post-translational modifications in the clinic. Biochim Biophys Acta (2012) 1.07
Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab (2015) 1.07
MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol (2003) 1.07
HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol (2002) 1.06
EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer Res (2003) 1.06
Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. J Natl Cancer Inst (2011) 1.05
Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab (2013) 1.05
Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery (2003) 1.05
Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response. Crit Rev Immunol (2011) 1.04
Cloning of S-adenosyl-L-methionine:C-24-Delta-sterol-methyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-Resistant promastigotes. Antimicrob Agents Chemother (2004) 1.04
Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab (2009) 1.03
Engagement of the inhibitory receptor CD158a interrupts TCR signaling, preventing dynamic membrane reorganization in CTL/tumor cell interaction. Blood (2002) 1.03
The acquisition of resistance to TNFα in breast cancer cells is associated with constitutive activation of autophagy as revealed by a transcriptome analysis using a custom microarray. Autophagy (2011) 1.02
New insight into the Nox4 subcellular localization in HEK293 cells: first monoclonal antibodies against Nox4. Biochimie (2010) 1.02
Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol (2002) 1.01
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer (2009) 1.01
Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab (2011) 1.01
NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol (2005) 1.01